ATC Group: B06AC09 Donidalorsen

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of B06AC09 in the ATC hierarchy

Level Code Title
1 B Blood and blood forming organs
2 B06 Other hematological agents
3 B06A Other hematological agents
4 B06AC Drugs used in hereditary angioedema
5 B06AC09

Active ingredients in B06AC09

Active Ingredient

Donidalorsen is a 2'-O-methoxyethyl–modified antisense oligonucleotide (ASO) conjugated to a triantennary N-acetylgalactosamine (GalNAc3) moiety that causes ribonuclease H1 (RNase H1) mediated degradation of prekallikrein (PKK) mRNA through selective binding to PKK mRNA, which results in reduced production of PKK protein. PKK is a pro-enzyme for plasma kallikrein, which results in the release of bradykinin, a potent vasodilator causing inflammation and swelling in hereditary angioedema (HAE).

Related product monographs

Document Type Information Source  
 DAWNZERA Solution for injection MPI, EU: SmPC European Medicines Agency (EU)
 DAWNZERA Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)

United States medicines

Medicines classified under this ATC code globally

Austria (AT)

Estonia (EE)

Lithuania (LT)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.